Zhi-Cheng Lai
Overview
Explore the profile of Zhi-Cheng Lai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
152
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang J, Xu Q, Che L, Lai Z, Tian W, Chen H
Zhongguo Zhong Yao Za Zhi
. 2024 Dec;
49(19):5238-5243.
PMID: 39701761
Four alkaloid compounds including one new compound and three known ones were isolated and extracted from the 70% ethanol extract of Nelumbinis Folium by silica gel column chromatography, octadecylsilyl(ODS) column...
2.
Xu Y, Lai Z, Kan A, Liu H, Huang Y, Lai Y, et al.
Front Biosci (Landmark Ed)
. 2024 Jul;
29(7):243.
PMID: 39082336
Background: The tumour mutation burden (TMB) is a valuable indicator of the accumulation of somatic mutations, and is thought to be associated with the biological behaviour and prognosis of tumours....
3.
Wen D, Huang L, Bu X, He M, Lai Z, Du Z, et al.
Cell Death Dis
. 2023 Nov;
14(11):769.
PMID: 38007497
Altered DNA methylation is a crucial epigenetic event in hepatocellular carcinoma (HCC) development and progression. Through methylation-transcriptomic analysis, we identified a set of sixty potential DNA methylation-based epidriver genes. In...
4.
He M, Li Q, Lai Z, Huang Y, Shi M
J Clin Oncol
. 2022 Mar;
40(16):1842-1843.
PMID: 35316070
No abstract available.
5.
Xu Y, Lai Z, He M, Bu X, Chen H, Zhou Y, et al.
Technol Cancer Res Treat
. 2021 Dec;
20:15330338211063848.
PMID: 34898313
Immunotherapy combined with chemotherapy have synergistic effects in multiple malignancies. We aimed to compare the efficacy and safety of toripalimab plus hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and...
6.
Liang R, Zhao Y, He M, Wen D, Bu X, Huang Y, et al.
Front Oncol
. 2021 May;
11:619461.
PMID: 34055599
Purpose: Our previous study showed that hepatic arterial infusion chemotherapy (HAIC) using oxaliplatin, fluorouracil, and leucovorin (FOLFOX) plus sorafenib provided a significant survival benefit over sorafenib for advanced hepatocellular carcinoma....
7.
He M, Liang R, Zhao Y, Xu Y, Chen H, Zhou Y, et al.
Ther Adv Med Oncol
. 2021 Apr;
13:17588359211002720.
PMID: 33854567
Background: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma, but prognosis is still unsatisfactory. Recently, hepatic arterial infusion chemotherapy (HAIC), and immune checkpoint inhibitors showed promising results for advanced...
8.
He M, Peng C, Zhao Y, Liang R, Lai Z, Kan A, et al.
Cancer Immunol Immunother
. 2021 Apr;
70(11):3207-3216.
PMID: 33813646
Background: Programmed cell death protein-1 (PD-1) inhibitor is recommended to treat advanced hepatocellular carcinoma (HCC). However, the safety of PD-1 inhibitor in patients with high HBV-DNA load is unknown because...
9.
Lai Z, Liang J, Chen L, Wang Z, Ruan S, Xie X, et al.
Life Sci
. 2018 Jun;
207:381-385.
PMID: 29924963
Aims: To determine if tumors located in the subcapsular space or in proximity to vessels would be a risk factor of local tumor progression (LTP) in hepatocellular carcinomas (HCC) after...